Lonza completes acquisition of Capsugel

摘要

Lonza has announced that following the receipt of all required regulatory approvals, it has completed the acquisition of Capsugel S.A. from KKR for USD 5.5 billion in cash, including refinancing of existing Capsugel debt of approximately USD 2 billion. The acquisition of Capsugel, a world leader in advanced oral dosage delivery technologies with a leading position in hard capsules, is expected to be accretive to Lonza's core earnings per share in the first full year post closing. This acquisition is in line with Lonza's stated strategy to accelerate growth and deliver value along the healthcare continuum by complementing its existing offerings and by opening up new market opportunities in the pharma and consumer healthcare and nutrition industries.